In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

No increased risk for thrombosis or bleeding seen with concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs.

The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously stopped being receptive to treatment finding their tumours shrinking, ...

New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, researchers found in a clinical trial. File Photo by Brian Kersey/UPI A powerful new ...

A new drug combo is offering hope for men with advanced prostate cancer. Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

News, features, and commentary about cancer-related issues ...